Review



scd1 inhibitor a939572  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    MedChemExpress scd1 inhibitor a939572
    Scd1 Inhibitor A939572, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 111 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/a939572/Oleic+acid/pm42208724-48-12-15
    Average 97 stars, based on 111 article reviews
    scd1 inhibitor a939572 - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells.
    Article Snippet: .. The cells were seeded (1 × 104per well) in 96-well culture plates and incubated overnight at 37 °C and 5% CO2 before treatment with the inhibitors alpelisib, inavolisib, A939572, and sulfosuccinimidyl oleate (SSO) (MedChemExpress, NJ, USA) for 72 h. All the drugs were dissolved using dimethyl sulfoxide as vesicle (Merck KGaA, DA, Germany). ..

    other:

    Article Title: Jacaric Acid Empowers RSL3-Induced Ferroptotic Cell Death in Two- and Three-Dimensional Breast Cancer Cell Models.
    Article Snippet: The stearoyl-CoA desaturase1 (SCD1) inhibitor, A939572, was purchased from Med-ChemExpress (Monmouth Junction, NJ, USA).

    Article Title: Targeting mTORC1 to promote ferroptosis and apoptosis in endometrial cancer with PI3K-Akt-mTOR pathway mutation.
    Article Snippet: CCI-779 (Temsirolimus, MedChem Express HY-50910), RMC-6272 (RM-006, MedChem Express HY-134904), A939572 (MedChem Express HY-50709), Necrostatin-1 (MedChem Express HY-15760), Z-VAD-FMK (MedChem Express HY-16658), Solutol HS-15 (MedChem Express HY-Y1893), and JKE-1674 (MedChem Express HY-138153) were purchased from MedChem Express.

    Article Title: Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors.
    Article Snippet: Ethnopharmacological relevance: Paris polyphylla Smith var. yunnanensis (Franch.). Hand.-Mazz. is a well-known medicinal herb valued in traditional medicine for its antitumor properties.. Its primary bioactive constituents, saponins, exert anti-bladder cancer effects by suppressing lipid metabolism.

    Article Title: Jacaric Acid Empowers RSL3-Induced Ferroptotic Cell Death in Two- and Three-Dimensional Breast Cancer Cell Models
    Article Snippet: The stearoyl-CoA desaturase1 (SCD1) inhibitor, A939572, was purchased from Med-ChemExpress (Monmouth Junction, NJ, USA).



    Similar Products

    scd1 inhibitor a939572  (MedChemExpress)
    97
    MedChemExpress scd1 inhibitor a939572
    Scd1 Inhibitor A939572, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/a939572/Oleic+acid/pm42208724-48-12-15
    Average 97 stars, based on 1 article reviews
    scd1 inhibitor a939572 - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    a939572 t4515  (TargetMol)
    94
    TargetMol a939572 t4515
    VA analogues inhibit ferroptosis through the regulation of MUFA metabolism. (A, B) Lipidomic analysis of MUFAs and PUFAs in membrane lipids including PE (A) and PC (B) following VA (5 μmol/L) and D3 (5 μmol/L) treatment for 12 h in HT-1080 cells. (C) Viability HT-1080 cells treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L) or ATRA (10 μmol/L) in the presence or absence of SCD1 inhibitor <t>A939572</t> (20 μmol/L) for 24 h. (D) Validation of SCD1 KO in HT-1080 cells. (E) The levels of OA-CoA were decreased in SCD1 knockout HT-1080 cells. (F) Viability of Vector and SCD1 KO cells treated with RSL3 for 24 h. (G) SCD1 KO compromised the anti-ferroptotic effect of VA analogues in HT-1080 cells. Cells were treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. (H, I) Supplement of OA restored the protective effect of VA analogues against ferroptosis. Vector and SCD1 KO HT-1080 cells were pretreated with OA in (10 and 20 μmol/L in panel H, and 10 μmol/L in panel I, followed by treatment with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. All the data are presented as the mean ± SD ( n = 3). ∗ P < 0.05, ∗∗∗ P < 0.001, indicating significant differences between groups.
    A939572 T4515, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/a939572/A939572/pmc13031062-278-20-25
    Average 94 stars, based on 1 article reviews
    a939572 t4515 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    scd1 inhibitor a939572  (TargetMol)
    94
    TargetMol scd1 inhibitor a939572
    VA analogues inhibit ferroptosis through the regulation of MUFA metabolism. (A, B) Lipidomic analysis of MUFAs and PUFAs in membrane lipids including PE (A) and PC (B) following VA (5 μmol/L) and D3 (5 μmol/L) treatment for 12 h in HT-1080 cells. (C) Viability HT-1080 cells treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L) or ATRA (10 μmol/L) in the presence or absence of SCD1 inhibitor <t>A939572</t> (20 μmol/L) for 24 h. (D) Validation of SCD1 KO in HT-1080 cells. (E) The levels of OA-CoA were decreased in SCD1 knockout HT-1080 cells. (F) Viability of Vector and SCD1 KO cells treated with RSL3 for 24 h. (G) SCD1 KO compromised the anti-ferroptotic effect of VA analogues in HT-1080 cells. Cells were treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. (H, I) Supplement of OA restored the protective effect of VA analogues against ferroptosis. Vector and SCD1 KO HT-1080 cells were pretreated with OA in (10 and 20 μmol/L in panel H, and 10 μmol/L in panel I, followed by treatment with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. All the data are presented as the mean ± SD ( n = 3). ∗ P < 0.05, ∗∗∗ P < 0.001, indicating significant differences between groups.
    Scd1 Inhibitor A939572, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/a939572/A939572/10__7150_slash_ijbs__126269-71-1-5
    Average 94 stars, based on 1 article reviews
    scd1 inhibitor a939572 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    a939572  (TargetMol)
    94
    TargetMol a939572
    VA analogues inhibit ferroptosis through the regulation of MUFA metabolism. (A, B) Lipidomic analysis of MUFAs and PUFAs in membrane lipids including PE (A) and PC (B) following VA (5 μmol/L) and D3 (5 μmol/L) treatment for 12 h in HT-1080 cells. (C) Viability HT-1080 cells treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L) or ATRA (10 μmol/L) in the presence or absence of SCD1 inhibitor <t>A939572</t> (20 μmol/L) for 24 h. (D) Validation of SCD1 KO in HT-1080 cells. (E) The levels of OA-CoA were decreased in SCD1 knockout HT-1080 cells. (F) Viability of Vector and SCD1 KO cells treated with RSL3 for 24 h. (G) SCD1 KO compromised the anti-ferroptotic effect of VA analogues in HT-1080 cells. Cells were treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. (H, I) Supplement of OA restored the protective effect of VA analogues against ferroptosis. Vector and SCD1 KO HT-1080 cells were pretreated with OA in (10 and 20 μmol/L in panel H, and 10 μmol/L in panel I, followed by treatment with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. All the data are presented as the mean ± SD ( n = 3). ∗ P < 0.05, ∗∗∗ P < 0.001, indicating significant differences between groups.
    A939572, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/a939572/A939572/10__7150_slash_ijbs__126269-114-54-56
    Average 94 stars, based on 1 article reviews
    a939572 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    a939572  (MedChemExpress)
    95
    MedChemExpress a939572
    VA analogues inhibit ferroptosis through the regulation of MUFA metabolism. (A, B) Lipidomic analysis of MUFAs and PUFAs in membrane lipids including PE (A) and PC (B) following VA (5 μmol/L) and D3 (5 μmol/L) treatment for 12 h in HT-1080 cells. (C) Viability HT-1080 cells treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L) or ATRA (10 μmol/L) in the presence or absence of SCD1 inhibitor <t>A939572</t> (20 μmol/L) for 24 h. (D) Validation of SCD1 KO in HT-1080 cells. (E) The levels of OA-CoA were decreased in SCD1 knockout HT-1080 cells. (F) Viability of Vector and SCD1 KO cells treated with RSL3 for 24 h. (G) SCD1 KO compromised the anti-ferroptotic effect of VA analogues in HT-1080 cells. Cells were treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. (H, I) Supplement of OA restored the protective effect of VA analogues against ferroptosis. Vector and SCD1 KO HT-1080 cells were pretreated with OA in (10 and 20 μmol/L in panel H, and 10 μmol/L in panel I, followed by treatment with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. All the data are presented as the mean ± SD ( n = 3). ∗ P < 0.05, ∗∗∗ P < 0.001, indicating significant differences between groups.
    A939572, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/a939572/A939572/pm41458042-37-10-11
    Average 95 stars, based on 1 article reviews
    a939572 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    VA analogues inhibit ferroptosis through the regulation of MUFA metabolism. (A, B) Lipidomic analysis of MUFAs and PUFAs in membrane lipids including PE (A) and PC (B) following VA (5 μmol/L) and D3 (5 μmol/L) treatment for 12 h in HT-1080 cells. (C) Viability HT-1080 cells treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L) or ATRA (10 μmol/L) in the presence or absence of SCD1 inhibitor A939572 (20 μmol/L) for 24 h. (D) Validation of SCD1 KO in HT-1080 cells. (E) The levels of OA-CoA were decreased in SCD1 knockout HT-1080 cells. (F) Viability of Vector and SCD1 KO cells treated with RSL3 for 24 h. (G) SCD1 KO compromised the anti-ferroptotic effect of VA analogues in HT-1080 cells. Cells were treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. (H, I) Supplement of OA restored the protective effect of VA analogues against ferroptosis. Vector and SCD1 KO HT-1080 cells were pretreated with OA in (10 and 20 μmol/L in panel H, and 10 μmol/L in panel I, followed by treatment with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. All the data are presented as the mean ± SD ( n = 3). ∗ P < 0.05, ∗∗∗ P < 0.001, indicating significant differences between groups.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: Vitamin A and its analogues modulate MUFAs metabolism to improve ferroptosis and aging by direct targeting of ACSL3

    doi: 10.1016/j.apsb.2025.11.004

    Figure Lengend Snippet: VA analogues inhibit ferroptosis through the regulation of MUFA metabolism. (A, B) Lipidomic analysis of MUFAs and PUFAs in membrane lipids including PE (A) and PC (B) following VA (5 μmol/L) and D3 (5 μmol/L) treatment for 12 h in HT-1080 cells. (C) Viability HT-1080 cells treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L) or ATRA (10 μmol/L) in the presence or absence of SCD1 inhibitor A939572 (20 μmol/L) for 24 h. (D) Validation of SCD1 KO in HT-1080 cells. (E) The levels of OA-CoA were decreased in SCD1 knockout HT-1080 cells. (F) Viability of Vector and SCD1 KO cells treated with RSL3 for 24 h. (G) SCD1 KO compromised the anti-ferroptotic effect of VA analogues in HT-1080 cells. Cells were treated with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. (H, I) Supplement of OA restored the protective effect of VA analogues against ferroptosis. Vector and SCD1 KO HT-1080 cells were pretreated with OA in (10 and 20 μmol/L in panel H, and 10 μmol/L in panel I, followed by treatment with RSL3 (0.5 μmol/L) and VA (1 μmol/L), ATRA (10 μmol/L) or D3 (5 μmol/L) for 24 h. All the data are presented as the mean ± SD ( n = 3). ∗ P < 0.05, ∗∗∗ P < 0.001, indicating significant differences between groups.

    Article Snippet: All- trans -retinal (T5256), Fenretinide (T1872), Acitretin (T1330), AGN193109 (TQ0097), HX531( T22843 ), Ch55 ( T14946 ), Adapalene (T1093) and A939572 (T4515) were purchased from TargetMOI (Shanghai, China).

    Techniques: Analogues, Membrane, Biomarker Discovery, Knock-Out, Plasmid Preparation